These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 18306355)

  • 1. Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients.
    Degen M; Brellier F; Schenk S; Driscoll R; Zaman K; Stupp R; Tornillo L; Terracciano L; Chiquet-Ehrismann R; Rüegg C; Seelentag W
    Int J Cancer; 2008 Jun; 122(11):2454-61. PubMed ID: 18306355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior.
    Degen M; Brellier F; Kain R; Ruiz C; Terracciano L; Orend G; Chiquet-Ehrismann R
    Cancer Res; 2007 Oct; 67(19):9169-79. PubMed ID: 17909022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenascin-C tissue concentration in inflammatory and neoplastic diseases of the colon mucosa.
    Riedl S; Kadmon M; Tandara A; Hinz U; Möller P; Faissner A
    Anticancer Res; 1997; 17(4B):3165-6. PubMed ID: 9329627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenascin-C serum levels and its prognostic power in non-small cell lung cancer.
    Gebauer F; Gelis S; Zander H; Meyer KF; Wolters-Eisfeld G; Izbicki JR; Bockhorn M; Tachezy M
    Oncotarget; 2016 Apr; 7(15):20945-52. PubMed ID: 26967391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cathepsin B expression in colorectal cancer in a Middle East population: Potential value as a tumor biomarker for late disease stages.
    Abdulla MH; Valli-Mohammed MA; Al-Khayal K; Al Shkieh A; Zubaidi A; Ahmad R; Al-Saleh K; Al-Obeed O; McKerrow J
    Oncol Rep; 2017 Jun; 37(6):3175-3180. PubMed ID: 28440429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro.
    Scherberich A; Tucker RP; Degen M; Brown-Luedi M; Andres AC; Chiquet-Ehrismann R
    Oncogene; 2005 Feb; 24(9):1525-32. PubMed ID: 15592496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of serum tenascin-C levels in breast cancer.
    Tastekin D; Tas F; Karabulut S; Duranyildiz D; Serilmez M; Guveli M; Vatansever S
    Tumour Biol; 2014 Jul; 35(7):6619-25. PubMed ID: 24696262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin.
    Takahashi N; Kawanishi-Tabata R; Haba A; Tabata M; Haruta Y; Tsai H; Seon BK
    Clin Cancer Res; 2001 Mar; 7(3):524-32. PubMed ID: 11297243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of the expression level of protein tyrosine phosphatase PRL-3 protein with liver metastasis and prognosis of patients with colorectal cancer.
    Peng L; Ning J; Meng L; Shou C
    J Cancer Res Clin Oncol; 2004 Sep; 130(9):521-6. PubMed ID: 15133662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma.
    Emoto K; Yamada Y; Sawada H; Fujimoto H; Ueno M; Takayama T; Kamada K; Naito A; Hirao S; Nakajima Y
    Cancer; 2001 Sep; 92(6):1419-26. PubMed ID: 11745218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients.
    Toiyama Y; Miki C; Inoue Y; Okugawa Y; Tanaka K; Kusunoki M
    Int J Cancer; 2009 Oct; 125(7):1657-62. PubMed ID: 19569242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
    Wu ZS; Wu Q; Yang JH; Wang HQ; Ding XD; Yang F; Xu XC
    Int J Cancer; 2008 May; 122(9):2050-6. PubMed ID: 18172859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tissue and serum galectin-1 expression in patients with colorectal carcinoma.
    Sheng TH; Rong LX; Li ZY; Bo J; Lei S
    Hepatogastroenterology; 2012; 59(114):389-94. PubMed ID: 22353504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tenascin-W is a better cancer biomarker than tenascin-C for most human solid tumors.
    Brellier F; Martina E; Degen M; Heuzé-Vourc'h N; Petit A; Kryza T; Courty Y; Terracciano L; Ruiz C; Chiquet-Ehrismann R
    BMC Clin Pathol; 2012 Sep; 12():14. PubMed ID: 22947174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Cystatin SN as a novel tumor marker for colorectal cancer.
    Yoneda K; Iida H; Endo H; Hosono K; Akiyama T; Takahashi H; Inamori M; Abe Y; Yoneda M; Fujita K; Kato S; Nozaki Y; Ichikawa Y; Uozaki H; Fukayama M; Shimamura T; Kodama T; Aburatani H; Miyazawa C; Ishii K; Hosomi N; Sagara M; Takahashi M; Ike H; Saito H; Kusakabe A; Nakajima A
    Int J Oncol; 2009 Jul; 35(1):33-40. PubMed ID: 19513549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated serum synuclein-gamma in patients with gastrointestinal and esophageal carcinomas.
    Liu C; Ma H; Qu L; Wu J; Meng L; Shou C
    Hepatogastroenterology; 2012 Oct; 59(119):2222-7. PubMed ID: 22440249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
    Melotte V; Lentjes MH; van den Bosch SM; Hellebrekers DM; de Hoon JP; Wouters KA; Daenen KL; Partouns-Hendriks IE; Stessels F; Louwagie J; Smits KM; Weijenberg MP; Sanduleanu S; Khalid-de Bakker CA; Oort FA; Meijer GA; Jonkers DM; Herman JG; de Bruïne AP; van Engeland M
    J Natl Cancer Inst; 2009 Jul; 101(13):916-27. PubMed ID: 19535783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of large tenascin-C spliced variant as a potential biomarker for colorectal cancer.
    Takeda A; Otani Y; Iseki H; Takeuchi H; Aikawa K; Tabuchi S; Shinozuka N; Saeki T; Okazaki Y; Koyama I
    World J Surg; 2007 Feb; 31(2):388-94. PubMed ID: 17219282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stromal tenascin distribution as a prognostic marker in colorectal cancer.
    Kressner U; Lindmark G; Tomasini-Johansson B; Bergström R; Gerdin B; Påhlman L; Glimelius B
    Br J Cancer; 1997; 76(4):526-30. PubMed ID: 9275031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic analysis of stromal proteins in different stages of colorectal cancer establishes Tenascin-C as a stromal biomarker for colorectal cancer metastasis.
    Li M; Peng F; Li G; Fu Y; Huang Y; Chen Z; Chen Y
    Oncotarget; 2016 Jun; 7(24):37226-37237. PubMed ID: 27191989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.